Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER-targeted therapy in HER2 amplification-positive and HER2 mutation-positive amplification-negative patients.
Genomic loss of HLA alleles may affect the clinical outcome in low-risk myelodysplastic syndrome patients.
Oncotarget
Montes, Paola P; Kerick, Martin M; Bernal, Mónica M; Hernández, Francisca F; Jiménez, Pilar P; Garrido, Pilar P; Márquez, Ana A; Jurado, Manuel M; Martin, Javier J; Garrido, Federico F; Ruiz-Cabello, Francisco F